erdafitinib
Selected indexed studies
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. (N Engl J Med, 2023) [PMID:37870920]
- Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. (Lancet Oncol, 2023) [PMID:37541273]
- Erdafitinib. (, 2012) [PMID:34633784]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. (2023) pubmed
- Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. (2023) pubmed
- Erdafitinib. (2012) pubmed
- Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. (2024) pubmed
- Erdafitinib. (2006) pubmed
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. (2019) pubmed
- Erdafitinib to treat urothelial carcinoma. (2019) pubmed
- Erdafitinib for the treatment of urothelial cancer. (2019) pubmed
- Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. (2020) pubmed
- Erdafitinib for the treatment of metastatic bladder cancer. (2020) pubmed